Ultragenyx Pharmaceutical
RARE
RARE
227 hedge funds and large institutions have $2.76B invested in Ultragenyx Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 88 increasing their positions, 77 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.85% more ownership
Funds ownership: 97.01% → 97.86% (+0.85%)
12% less call options, than puts
Call options by funds: $9.19M | Put options by funds: $10.4M
12% less capital invested
Capital invested by funds: $3.14B → $2.76B (-$385M)
Holders
227
Holding in Top 10
5
Calls
$9.19M
Puts
$10.4M
Top Buyers
| 1 | +$26.4M | |
| 2 | +$22.9M | |
| 3 | +$21.5M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.5M |
Top Sellers
| 1 | -$34.6M | |
| 2 | -$26.8M | |
| 3 | -$22.8M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$22.2M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$18.6M |